Sockel K, Wermke M, Radke J, Kiani A, Schaich M, Bornhäuser M, Ehninger G, Thiede C, Platzbecker U. Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse. Haematologica [Internet]. 2011Oct.4 [cited 2026Nov.3];96(10):1568-70. Available from: https://haematologica.org/article/view/6110